Ketamine alleviates depression through several mechanisms:
1. NMDA Receptor Antagonism
Ketamine is a non-competitive antagonist of the N-methyl-D-aspartate (NMDA) receptor, a subtype of glutamate receptor. By blocking NMDA receptors, ketamine increases glutamate release, which then activates the AMPA receptors. This activation leads to a cascade of events resulting in the release of brain-derived neurotrophic factor (BDNF), crucial for synaptic plasticity and neurogenesis, which are essential for mood regulation (National Institute on Aging) .
2. Synaptic Plasticity
Ketamine promotes synaptic plasticity, which involves the strengthening and formation of new synaptic connections in the brain. This is particularly important in brain regions like the prefrontal cortex and hippocampus, which are implicated in mood regulation and cognitive functions. Enhanced synaptic plasticity helps restore neural circuits that are often impaired in depression .
3. Anti-inflammatory Effects
Depression is associated with elevated levels of pro-inflammatory cytokines. Ketamine has been shown to have anti-inflammatory effects, reducing the levels of these cytokines and thereby alleviating depressive symptoms. This anti-inflammatory action contributes to its rapid antidepressant effects .
4. Modulation of GABA and Other Neurotransmitter Systems
Ketamine influences the gamma-aminobutyric acid (GABA) system and other neurotransmitter systems, contributing to its antidepressant effects. By modulating these systems, ketamine helps balance the excitatory and inhibitory signals in the brain, which is often disrupted in depression.
5. Restoration of Default Mode Network (DMN)
The DMN, involved in self-referential thought processes, is often hyperactive in individuals with depression. Ketamine has been found to help normalize the activity within the DMN, thus reducing the negative rumination commonly seen in depression .
Overall, ketamine’s multifaceted actions on neural pathways and synaptic connections contribute to its rapid and robust antidepressant effects, often observed within hours of administration.
References
- NIH, NIA statement on donanemab results. Link
- Lilly’s Donanemab study. Link
- Clinical Pharmacology & Therapeutics. Ketamine as an antidepressant: Overview and future perspectives.
- Biological Psychiatry. Mechanisms of ketamine’s antidepressant actions: Evidence and future directions.
